Form 4: Petros Pharma Director Gains 4.375M RSUs

Petros Pharmaceuticals Director Joshua Silverman acquired 4,375,000 Restricted Stock Units, with a vesting schedule tied to continued service, adjusted for a recent reverse stock split.

Summary

• Joshua Silverman, a Director of Petros Pharmaceuticals, Inc. (PTPI), acquired 4,375,000 Restricted Stock Units (RSUs).
• The transaction date for this acquisition was January 2, 2026.
• Each RSU represents the right to receive one share of Petros Pharmaceuticals' common stock.
• 50% of the granted RSUs vested on the date of grant, and the remaining 50% will vest on the six-month anniversary of the grant date, contingent on Mr. Silverman providing services to the Issuer.
• Following this transaction, Mr. Silverman beneficially owns 4,415,450 shares of common stock.
• The reported beneficial ownership amount has been adjusted for the Issuer's 1-for-25 reverse stock split, which became effective on April 30, 2025, at 4:05 p.m. New York time.

Sentiment

Score: 6

Explanation: The grant of equity compensation to a director is generally viewed as a neutral to slightly positive event, as it fosters alignment between management and shareholder interests, though it also implies potential future dilution.

Positives

• The grant of a significant number of Restricted Stock Units to a director aligns their long-term interests with those of the shareholders, promoting commitment to the company's success.
• The vesting schedule, tied to continued service, incentivizes the director to remain with the company and contribute to its performance over time.

Risks

• Potential future dilution for existing shareholders when the RSUs convert into common stock.

Future Outlook

The vesting schedule for the remaining 50% of the RSUs on the six-month anniversary of the grant date indicates an expectation of continued service from the reporting person.

Industry Context

Equity compensation, such as Restricted Stock Units, is a standard practice across various industries to attract, retain, and incentivize key management and directors by aligning their financial interests with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• Not directly comparable as this filing reports an individual insider transaction rather than company performance metrics or operational results. The use of RSUs for director compensation is a common practice in publicly traded companies.

Related Party Transactions

• The grant of 4,375,000 Restricted Stock Units to Joshua Silverman, a Director of Petros Pharmaceuticals, Inc., constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential for future dilution upon conversion of RSUs into common stock, but also improved alignment of director's interests with long-term shareholder value.
• Employees (specifically Joshua Silverman): Increased equity stake and long-term incentive tied to company performance and continued service.

Next Steps

• The remaining 50% of the granted RSUs will vest on the six-month anniversary of the grant date, provided Joshua Silverman continues to provide services to the Issuer.

Key Dates

Keywords

Petros Pharmaceuticals, PTPI, Joshua Silverman, Form 4, Restricted Stock Units, RSU, Equity Compensation, Director, Insider Transaction, Stock Grant, Reverse Stock Split